Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

Publisher： Karger

E-ISSN： 1423-0232|83|4|192-200

ISSN： 0030-2414

Source： Oncology, Vol.83, Iss.4, 2012-08, pp. : 192-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 251-258

Karger

Access to resources Recommend Favorite

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602

By Sato Yozo  

Upsala Journal of Medical Sciences, Vol. 118, Iss. 1, 2013-03 ,pp. : 16-22

Informa Healthcare

Access to resources Recommend Favorite

Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization

By  

Oncology, Vol. 91, Iss. 6, 2016-10 ,pp. : 317-330

Karger

Access to resources Recommend Favorite

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1111-1121

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1111-1121

John Wiley & Sons Inc

Access to resources Recommend Favorite